AcroMeta Group Limited (SGX: 43F) has announced a strategic partnership with Macro HRD SG Pte. Ltd. (Macro HRD), a Singapore-based provider of management consultancy services to the healthcare sector. The partnership is centered on Macro-ATCLS Pte. Ltd., the company through which Macro HRD’s Ambient Temperature Cellular Logistics (ATCLS) technology is being commercialized. The non-binding term sheet outlines AcroMeta’s intention to acquire a strategic stake in Macro-ATCLS and includes an option to acquire an exclusive license to deploy the ATCLS platform across Southeast Asia.
ATCLS is an emerging technology designed to transform the transportation and distribution of living cells and other temperature-sensitive biological materials by eliminating reliance on conventional refrigerated and cryogenic cold chains. It uses proprietary ambient-temperature preservation and reactivation technologies, supported by its Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity, and process control. This enables dormant living cells to be transported at ambient temperature and reactivated at the point of use.
The technology addresses rapidly expanding markets including stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, organ and tissue transplantation, and cell-and-gene-therapy logistics. According to data provided by Macro's management, the underlying markets range from US$5.2 billion for immune-cell therapy to US$47 billion for organ transplantation, while the global cell-and-gene-therapy 3PL market is estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035 (25.1% CAGR). Based on defined ambient-addressable segments, ATCLS estimates a Serviceable Addressable Market (SAM) of approximately US$14.5 billion by 2032.
Mr Lawrence Toh, Executive Director of AcroMeta, commented, “This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead. We see this as a natural extension of our strategy to grow our portfolio beyond our core operations, and we’re excited about the potential to build a meaningful presence in bringing this technology into Southeast Asia.”
The proposed exclusive licensing arrangement would grant AcroMeta the rights to develop and commercialize the ATCLS business within Southeast Asia, including the right to appoint sub-licensees. This structure also provides a first right to acquire additional territories, significantly expanding the Group’s potential commercial reach.
The Group intends to continue evaluating strategic opportunities to support long-term value creation for shareholders. The Board remains focused on disciplined capital allocation as the Group progresses through its next phase of development.
This announcement underscores the growing importance of advanced logistics solutions in the biotech sector, as the need for efficient and cost-effective transportation of cell and gene therapies becomes critical. By entering this niche, AcroMeta positions itself to benefit from the sector's projected growth, while also diversifying its revenue streams beyond facility management.
For more information on AcroMeta, visit www.AcroMeta.com. For details on the original release, see www.newmediawire.com.
